Pancreatic Cancer Drug Doubles Survival, Ships to Patients

An experimental pancreatic cancer treatment that helped patients live nearly twice as long as standard chemotherapy is now reaching patients before formal FDA approval.

Revolution Medicines began shipping daraxonrasib to physicians this week through a special early access program.